Is Lifecore Biomedical, Inc. (LFCR) a Buy, Sell, or Hold?
NASDAQ : LFCR
Lifecore Biomedical, Inc.
$5.01 USD
$0.17 (3.51%)
- Volume
- 156.69K
- Average Volume
- 200.58K
- Market Capitalization
- $187.92M
- P/E Ratio
- -5.45
- Dividend Yield
- 0.00%
- Price Target
- $6.50
- Year High
- $8.98
- Year Low
- $3.63
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.87
Company Overview
NASDAQ
Paul Josephs
Drug Manufacturers - Specialty & Generic
Healthcare
LFCR
406
US
USD
Liquidity Metrics
9.64
3.87
2.69
0.80
0.00
Sales & Valuation
$129.46M
1.58
10.35
-2311.89
0.00
Profitability
-$0.93
-$30.79M
-24.30%
-23.80%
-194.95%
-12.63%
P/E Metrics
-5.45
-0.20
-0.20
Analyst Price Target & Rating
$6.50
$6.50
$6.50
2/5
7 Analysts
-22.92%
Financial Health Scores
-0.08
5/9
$62.05M
$229.5M
$213.41M
$4.83M
Key Metrics (TTM)
$319.37M
2.68
24.05
3.87
-194.95%
-0.49%
-18.00%
-0.04%
173 days
Company Executives
| Name | Title |
|---|---|
| Aaron Perlitsh | Director of Internal Audit & Chief Compliance Officer |
| Paul Josephs | President, Chief Executive Officer & Director |
| Thomas Salus | Chief Legal and Administration Officer & Corporate Secretary |
| Parker K. Javid | Vice President |
| Jackie Q. Klecker | Executive Vice President of Quality & Development Services |
| Ryan D. Lake | Executive Vice President & Chief Financial Officer |
| Thomas Guldager | Senior Vice President of Operations |
| Mark DaFonseca | Chief Commercial Officer |
Poll Results
No votes yet today — be the first to share your view!
About Lifecore Biomedical, Inc. (NASDAQ:LFCR) Stock
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development ser ... vices, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
Lifecore Biomedical, Inc. (LFCR) Q2 2026 Earnings Call Transcript
2026-08-05 14:10:10
Lifecore Biomedical, Inc. (LFCR) Q2 2026 Earnings Call Transcript
2026-08-05 07:05:00
-- Reaffirms 2026 Guidance -- -- Multiple New Business Wins, Adding Impactful Programs to Pipeline -- -- Cost Reduction and Productivity Enhancements Continue to Strengthen Organization -- Conference Call Today at 8:00am ET CHASKA, Minn., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced results for the second quarter and six months ended June 30, 2026.
2026-07-29 16:05:00
CHASKA, Minn., July 29, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the second quarter ended June 30, 2026, on Wednesday, August 5, 2026, before the market opens.
Lifecore Biomedical Signs Three New Customer Agreements
2026-07-28 07:05:00
--Technology Transfer Agreement for Regenerative Medicine Late-Stage Development Program-- --Two Additional Agreements Supporting Early-Stage Programs Including Formulation and Development for a Global Medical Technology Company -- -- All Programs are Additive to Lifecore's High-Value Pipeline and Expected to Contribute to 2028 Revenue -- CHASKA, Minn., July 28, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced it has signed three new customer agreements, further expanding its pipeline of early- and late-stage programs.
Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-07-15 16:05:00
CHASKA, Minn. , July 15, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecore") a fully integrated injectables contract development and manufacturing organization ("CDMO"), today announced that effective on July 13, 2026, Lifecore granted a restricted stock unit ("RSU") award with respect to 3,500 shares of its common stock under Lifecore's Equity Inducement Plan, as amended (the "Inducement Plan") to a newly hired employee of Lifecore.
Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-07-15 16:05:00
CHASKA, Minn., July 15, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that effective on July 13, 2026, Lifecore granted a restricted stock unit (“RSU”) award with respect to 3,500 shares of its common stock under Lifecore's Equity Inducement Plan, as amended (the “Inducement Plan”) to a newly hired employee of Lifecore.
Lifecore Biomedical Signs New Agreement with Global Pharmaceutical Company
2026-06-15 07:05:00
--Agreement Supports Tech Transfer and Commercial Manufacturing of Currently Marketed Neurology Product-- --Seventh Addition to Lifecore's Late-Stage Pipeline in Seven Months-- CHASKA, Minn., June 15, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced it has signed a new agreement with a global pharmaceutical company.
Lifecore Biomedical Signs Agreement with New Biopharmaceutical Customer
2026-06-02 07:05:00
-- Agreement Calls for Tech Transfer in Preparation for Potential Commercial Manufacturing of Injectable Ophthalmic Product -- -- Sixth Addition to Late-Stage Pipeline in Seven Months -- CHASKA, Minn., June 02, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that it has signed a manufacturing services agreement with a leading provider of ophthalmic disease management solutions.
Frequently Asked Questions
-
What is the current Lifecore Biomedical, Inc. (LFCR) stock price?
-
Lifecore Biomedical, Inc.(NASDAQ:LFCR) stock price is $5.01 in the last trading session. During the trading session, LFCR stock reached the peak price of $8.98 while $3.63 was the lowest point it dropped to. The percentage change in LFCR stock occurred in the recent session was 3.51% while the dollar amount for the price change in LFCR stock was $0.17.
-
LFCR's industry and sector of operation?
-
The NASDAQ listed LFCR is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.
-
Who are the executives of LFCR?
-
Aaron Perlitsh | Director of Internal Audit & Chief Compliance Officer
Paul Josephs | President, Chief Executive Officer & Director
Thomas Salus | Chief Legal and Administration Officer & Corporate Secretary
Parker K. Javid | Vice President
Jackie Q. Klecker | Executive Vice President of Quality & Development Services -
How many employees does LFCR have?
-
Number of LFCR employees currently stands at 406. LFCR operates from 3515 Lyman Boulevard, Chaska, MN 55318, US.
-
Link for LFCR official website?
-
Official Website of LFCR is: https://www.lifecore.com
-
How do I contact LFCR?
-
LFCR could be contacted at phone #952 368 4300 and can also be accessed through its website. LFCR operates from 3515 Lyman Boulevard, Chaska, MN 55318, US.
-
How many shares of LFCR are traded daily?
-
The average number of LFCR shares traded daily for last 3 months was 200.58K.
-
What is the market cap of LFCR currently?
-
The market value of LFCR currently stands at $187.92M with its latest stock price at $5.01